Latest & greatest articles for magnesium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on magnesium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on magnesium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for magnesium

21. High-Dose Magnesium Sulfate Infusion for Severe Asthma in the Emergency Department: Efficacy Study

High-Dose Magnesium Sulfate Infusion for Severe Asthma in the Emergency Department: Efficacy Study PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

PedsCCM Evidence-Based Journal Club2016

22. Magnesium Sulfate Use in Obstetrics

Magnesium Sulfate Use in Obstetrics Magnesium Sulfate Use in Obstetrics - ACOG Menu ▼ Magnesium Sulfate Use in Obstetrics Page Navigation ▼ INTERIM UPDATE Number 652, January 2016 (Replaces Committee Opinion Number 573, September 2013) (Reaffirmed 2018) The American College of Obstetricians and Gynecologists Committee on Obstetric Practice Society for Maternal-Fetal Medicine This document reflects emerging clinical and scientific advances as of the date issued and is subject to change (...) . The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. INTERIM UPDATE: This Committee Opinion is updated to reflect a limited, focused change in gestational age at which to consider tocolysis. Magnesium Sulfate Use in Obstetrics ABSTRACT: The U.S. Food and Drug Administration advises against the use of magnesium sulfate injections for more than 5–7 days to stop preterm labor in pregnant women. Based on this, the drug classification was changed from

American College of Obstetricians and Gynecologists2016

23. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children

A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children 26232172 2015 10 02 2016 01 06 2016 12 15 1528-0020 126 14 2015 Oct 01 Blood Blood A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. 1651-7 10.1182/blood-2015-05-647107 Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises. We hypothesized that intravenous (...) magnesium would shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL) for pediatric patients hospitalized with sickle cell pain crises. The Magnesium for Children in Crisis (MAGiC) study was a randomized, double-blind, placebo-controlled trial of intravenous magnesium vs normal saline placebo conducted at 8 sites within the Pediatric Emergency Care Applied Research Network (PECARN). Children 4 to 21 years old with hemoglobin SS or Sβ(0) thalassemia requiring

EvidenceUpdates2016

24. Intravenous Magnesium Sulphate for Refractory Torsades de Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines

Intravenous Magnesium Sulphate for Refractory Torsades de Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Refractory Torsades de Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Intravenous Magnesium Sulphate for Refractory Torsades de Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Refractory Torsades de (...) Pointes or Ventricular fibrillation: Clinical Effectiveness and Guidelines Published on: November 6, 2015 Project Number: RB0928-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of intravenous magnesium sulphate for patients with refractory torsades de pointes or ventricular fibrillation? What are the evidence-based guidelines regarding the administration of intravenous magnesium sulphate for patients

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

25. Magnesium aspartate dihydrate (Magnaspartate)

Magnesium aspartate dihydrate (Magnaspartate) Magnesium aspartate dihydrate (Magnaspartate) Magnesium aspartate dihydrate (Magnaspartate) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Magnesium aspartate dihydrate (Magnaspartate) Penarth: All Wales Therapeutics (...) and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2596. 2015 Authors' conclusions Magnesium aspartate dihydrate (Magnaspartate®) is recommended as an option for use within NHS Wales for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor, in adults, children and adolescents aged from two years. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adolescent; Adult

Health Technology Assessment (HTA) Database.2015

26. Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines

Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical Effectiveness and Guidelines Intravenous Magnesium Sulphate for Pre-Hospital Management of Refractory Asthma: Clinical (...) Effectiveness and Guidelines Published on: September 2, 2015 Project Number: RB0906-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of intravenous administration of magnesium sulphate for the treatment of acute and unrelieved, refractory asthma-related bronchospasm in prehospital settings? What are the evidence-based guidelines regarding the intravenous administration of magnesium sulphate for the treatment of acute

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

27. Magnesium aspartate dihydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency

Magnesium aspartate dihydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency %PDF-1.5 %���� 84 0 obj > endobj 102 0 obj >/Filter/FlateDecode/ID[ ]/Index[84 36]/Info 83 0 R/Length 89/Prev 199787/Root 85 0 R/Size 120/Type/XRef/W[1 2 1]>>stream h�bbd``b`�$��� �� ; $��@�w;�uD�� "HpG��) � ���G�0012 >stream h�b`````jb�^1�F fa�h@�b�!o���;Lf 3� ��,�(h�0�*xn����j��f��,��f�0�1���2*ѷ9 endstream endobj 85 0 obj >/Metadata 2 0 R/PageLayout/OneColumn/Pages 82 0 R/StructTreeRoot 6

All Wales Medicines Strategy Group2015

28. Magnesium aspartate dehydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency

Magnesium aspartate dehydrate (Magnaspartate) - for the treatment and prevention of magnesium deficiency Published 08 June 2015 Product Update magnesium aspartate dihydrate equivalent to 243mg (10mmol) of magnesium powder for oral solution (Magnaspartate ® ) SMC No. (1042/15) Kora Corporation Limited 6 March 2015 (Issued 05 June 2015) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs (...) ) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission magnesium aspartate dihydrate (Magnaspartate ® ) is accepted for use within NHS Scotland. Indication under review: for the treatment and prevention of magnesium deficiency, as diagnosed by a doctor This is the first licensed oral magnesium product to be available in the UK for the treatment and prevention of magnesium deficiency. Magnesium supplementation has previously been available

Scottish Medicines Consortium2015

29. Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block?

Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? BestBets: Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Does magnesium prolong the analgaesic effect of bupivicaine in a fascia iliaca nerve block? Report By: Dr Peter Kilgour, Dr Babajide Oni - Emergency Medicine ST2 Search checked by Dr Dianne Tabone , Dr Hisham Ghanayem (ST5) - Consultant in Emergency Medicine Preston and (ST5 Central Manchester (...) ) Institution: Royal Preston Hospital, Preston, Lancs, UK Date Submitted: 11th November 2014 Date Completed: 6th May 2015 Last Modified: 6th May 2015 Status: Green (complete) Three Part Question In [patients with a femoral neck fracture] does [magnesium prolong the analgaesic effect of bupivacaine] in [a fascia iliaca nerve block]? Clinical Scenario An 89-year-old woman presents to your emergency department following a fall. She is complaining of severe pain in her right hip area. A plain radiograph shows

BestBETS2015

30. Prehospital use of magnesium sulfate as neuroprotection in acute stroke.

Prehospital use of magnesium sulfate as neuroprotection in acute stroke. 25651247 2015 02 05 2015 02 19 2017 02 20 1533-4406 372 6 2015 Feb 05 The New England journal of medicine N. Engl. J. Med. Prehospital use of magnesium sulfate as neuroprotection in acute stroke. 528-36 10.1056/NEJMoa1408827 Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans (...) . Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents. We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate or placebo, beginning within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days

NEJM2015

31. Prehospital use of magnesium sulfate as neuroprotection in acute stroke.

Prehospital use of magnesium sulfate as neuroprotection in acute stroke. BACKGROUND: Magnesium sulfate is neuroprotective in preclinical models of stroke and has shown signals of potential efficacy with an acceptable safety profile when delivered early after stroke onset in humans. Delayed initiation of neuroprotective agents has hindered earlier phase 3 trials of neuroprotective agents. METHODS: We randomly assigned patients with suspected stroke to receive either intravenous magnesium sulfate (...) or placebo, beginning within 2 hours after symptom onset. A loading dose was initiated by paramedics before the patient arrived at the hospital, and a 24-hour maintenance infusion was started on the patient's arrival at the hospital. The primary outcome was the degree of disability at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability). RESULTS: Among the 1700 enrolled patients (857 in the magnesium group and 843 in the placebo

NEJM2015

32. Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations?

Does Intravenous Magnesium Reduce the Need for Hospital Admission Among Adult Patients With Acute Asthma Exacerbations? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2015

33. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation

Intrapartum magnesium sulfate and need for intensive delivery room resuscitation 25232002 2014 12 16 2015 02 19 2014 12 16 1468-2052 100 1 2015 Jan Archives of disease in childhood. Fetal and neonatal edition Arch. Dis. Child. Fetal Neonatal Ed. Intrapartum magnesium sulfate and need for intensive delivery room resuscitation. F59-65 10.1136/archdischild-2013-305884 To evaluate the association of intrapartum magnesium sulfate for fetal neuroprotection (MgSO4-FN) with the delivery room (...) Neuroprotective Agents 7487-88-9 Magnesium Sulfate YKH834O4BH Epinephrine AIM IM Bronchodilator Agents administration & dosage Delivery Rooms Epinephrine administration & dosage Female Gestational Age Heart Massage Humans Infant, Newborn Magnesium Sulfate administration & dosage Male Neuroprotective Agents Respiration, Artificial Resuscitation Retrospective Studies Treatment Outcome Neonatology Neurodevelopment Outcomes research Resuscitation 2014 9 19 6 0 2014 9 19 6 0 2015 2 20 6 0 ppublish 25232002

EvidenceUpdates2014

34. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo.

School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. IMPORTANCE: Antenatal magnesium sulfate given to pregnant women at imminent risk of very preterm delivery reduces the risk of cerebral palsy in early childhood, although its effects into school age have not been reported from randomized trials. OBJECTIVE: To determine the association between exposure to antenatal magnesium sulfate and neurological, cognitive, academic, and behavioral (...) outcomes at school age. DESIGN, SETTING, AND PARTICIPANTS: The ACTOMgSO4 was a randomized clinical trial conducted in 16 centers in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (n = 535 magnesium; n = 527 placebo) for whom imminent birth was planned or expected before 30 weeks' gestation. Children who survived from the 14 centers who participated in the school-age follow-up (n = 443 magnesium; n = 424 placebo) were invited for an assessment at 6 to 11

JAMA2014

35. Adults with acute asthma: can intravenous magnesium sulfate help?

Adults with acute asthma: can intravenous magnesium sulfate help? Adults with acute asthma: can intravenous magnesium sulfate help? - Evidently Cochrane Search and hit Go By May 30, 2014 // How useful is intravenous magnesium sulfate in treating people arriving in the Emergency Department with asthma attacks? Can it help some to avoid hospital admission? In this guest post, Dr Chris Cates looks at the latest evidence. The full report of the large “3Mg trial” of intravenous or nebulised (...) magnesium sulfate in adults with asthma exacerbations was published in April 2014[ ]. The authors concluded that they “were unable to demonstrate any clinically worthwhile benefit from magnesium sulphate in acute severe asthma”, and thereby questioned whether there was a place for using intravenous magnesium sulfate in adults with an asthma exacerbation who had not responded to the first line treatments of steroid tablets (on injections) in combination with nebulised salbutamol and ipratropium. However

Evidently Cochrane2014

36. The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma

The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma The 3Mg Trial: A randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from (...) the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Study aimed to determine whether intravenous (i.v.) or nebulised magnesium sulphate improves symptoms of breathlessness and reduces the need for hospital admission in adults with acute severe asthma. The results were unable to demonstrate a clinically worthwhile benefit from magnesium sulphate in acute severe asthma. There was some

NIHR HTA programme2014

37. Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores

Randomised controlled trial: The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here The addition of nebulised magnesium to the standard asthma therapy for children with severe symptoms results in small improvements in asthma severity scores Article

Evidence-Based Medicine (Requires free registration)2014

38. School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo.

School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. 25226476 2014 09 17 2014 10 20 2016 10 17 1538-3598 312 11 2014 Sep 17 JAMA JAMA School-age outcomes of very preterm infants after antenatal treatment with magnesium sulfate vs placebo. 1105-13 10.1001/jama.2014.11189 Antenatal magnesium sulfate given to pregnant women at imminent risk of very preterm delivery reduces the risk of cerebral palsy in early childhood, although its effects (...) into school age have not been reported from randomized trials. To determine the association between exposure to antenatal magnesium sulfate and neurological, cognitive, academic, and behavioral outcomes at school age. The ACTOMgSO4 was a randomized clinical trial conducted in 16 centers in Australia and New Zealand, comparing magnesium sulfate with placebo given to pregnant women (n = 535 magnesium; n = 527 placebo) for whom imminent birth was planned or expected before 30 weeks' gestation. Children who

JAMA2014

39. MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children

MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children MAGNEsium Trial In Children (MAGNETIC): a randomised, placebo controlled trial and economic evaluation of nebulised magnesium sulphate in acute severe asthma in children Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page

NIHR HTA programme2013

40. Magnesium for alcohol withdrawal.

Magnesium for alcohol withdrawal. BACKGROUND: Patients have been given magnesium to treat or prevent alcohol withdrawal syndrome (AWS). Evidence to support this practice is limited, and is often based on the controversial link between hypomagnesaemia and AWS. OBJECTIVES: To assess the effects of magnesium for the prevention or treatment of AWS in hospitalised adults. SEARCH METHODS: We searched the Cochrane Drugs and Alcohol Group Register of Controlled Trials (August 2012), PubMed (from 1966 (...) to August 2012 ), EMBASE (from 1988 to August 2012), CINAHL (from 1982 to March 2010), Web of Science (1965 to August 2012). We also carried out Internet searches. SELECTION CRITERIA: Randomised or quasi-randomised trials of magnesium for hospitalised adults with, or at risk for, acute alcohol withdrawal. DATA COLLECTION AND ANALYSIS: Two review authors independently extracted data with a standardised data extraction form, contacting the correspondence investigator if the necessary information

Cochrane2013